
3 Top Buffett Stocks to Buy and Hold for the Long Haul
Warren Buffett is one of the most closely followed investors in the world. Six decades ago, his fledgling fund acquired the struggling textile maker Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B). Buffett subsequently shut down Berkshire's textile business and transformed it into a diversified conglomerate with subsidiaries across the insurance, railroad, energy, and consumer staples sectors. Those subsidiaries generated plenty of cash for building Berkshire's investment portfolio.
Today, that portfolio is worth $276 billion and holds positions in 44 stocks. Many investors follow those stocks for investment ideas, but they're mostly conservative blue chips that won't skyrocket over the next few months.
If you can tune out the near-term noise and want some Buffett-backed stocks to hold for the long haul, you should consider investing in these three evergreen plays: Amazon (NASDAQ: AMZN), Visa (NYSE: V), and Chubb (NYSE: CB). All three companies dominate their respective markets with very wide moats.
1. Amazon
Amazon, the world's largest e-commerce and cloud infrastructure company, accounts for 0.70% of Berkshire's portfolio. It initially bought Amazon stock in the first quarter of 2019, and it now holds $1.98 billion worth with an average purchase price of $84.20. That investment has more than doubled in value over the past six years.
From 2019 to 2024, Amazon's revenue grew at a compound annual growth rate (CAGR) of 18% as its EPS rose at a CAGR of 37%. It logged impressive growth even as it weathered the pandemic, inflation, and other macro headwinds.
Amazon grew by expanding its e-commerce marketplace, locking more shoppers into its Prime subscriptions, and serving up more remote computing power and storage through its Amazon Web Services (AWS) cloud infrastructure platform. It usually subsidizes the growth of its lower-margin e-commerce business with AWS' higher-margin revenues, and that strategy gives it a formidable advantage against other retailers.
Amazon's scale should keep it ahead of its e-commerce and cloud competitors. It should also profit from the growth of the AI market, which will drive more companies to upgrade their cloud infrastructure to handle the latest AI services.
2. Visa
Visa, the world's top card payments processor, accounts for 1% of Berkshire's portfolio. It started buying Visa in the second quarter of 2011, and it now owns $2.75 billion in shares with an average purchase price of $52. That's a six-bagger gain in 14 years.
From 2011 to 2024, Visa's revenue and EPS increased at a CAGR of 11% and 19%, respectively. Like Amazon, Visa kept growing through several economic downturns.
Visa's business is resilient because it doesn't issue any cards or take on any debt. Instead, it only partners with banks and other financial institutions to issue co-branded cards. Those partners handle all the accounts and customer debt, while Visa only charges "swipe fees" of 1.5%-3.5% for every transaction processed on its network.
Visa and Mastercard share a near-duopoly in that market, so merchants are usually willing to pay those fees to attract more customers. Both companies are facing pressure from businesses and government regulators to lower those fees, but they'll likely dominate the card-based payment market for decades to come.
3. Chubb
Chubb is the biggest publicly traded provider of property, supplemental, health, and casualty insurance policies. Berkshire started to invest in Chubb in the third quarter of 2023, and that $7.95 billion stake now accounts for 2.9% of its portfolio. It paid an average price of $221 for those shares, so it's already sitting on a 33% gain.
Chubb's core operating income per share (excluding any tax benefits) grew 30% in 2023 and 13% in 2024. Its business was well insulated from inflation and rising interest rates, since its customers generally won't cancel their essential policies to save a few dollars. That's why its consolidated net premiums rose 13.5% in 2023 and 8.7% in 2024.
Chubb isn't an exciting investment, but it's a safe one to hold as the macro headwinds drive investors away from more consumer-driven and cyclical sectors. Moreover, Buffett notably increased Berkshire's exposure to Chubb even as it reduced its stakes in other top holdings like Apple and Bank of America while raising its cash and short-term Treasury holdings to record levels -- so Chubb could be a great way to ride out the near-term volatility and generate reliable long-term gains.
Don't miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $309,972!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $40,573!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $512,338!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.
Continue »
*Stock Advisor returns as of March 18, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
an hour ago
- Globe and Mail
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit ('RSU') awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the '2021 Inducement Plan'). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is used exclusively for granting equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $33.08 per share, which is equal to the closing price of Crinetics' common stock on the Nasdaq Global Select Market on June 10, 2025. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee's continued employment with Crinetics on such vesting dates. The RSUs will vest over four years in equal annual installments beginning on the one-year anniversary of the applicable vesting commencement date, also subject to each employee's continued employment with Crinetics on such vesting dates. The stock option and RSU awards are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of an applicable stock option award agreement or RSU award agreement covering the respective grant. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@ (858) 345-6340


Globe and Mail
an hour ago
- Globe and Mail
HP Inc. Declares Dividend
PALO ALTO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) has declared a cash dividend of $0.2894 per share on the company's common stock. The dividend, the fourth in HP's fiscal year 2025, is payable on October 1, 2025, to stockholders of record as of the close of business on September 10, 2025. HP has approximately 0.9 billion shares of common stock outstanding. About HP Inc. HP Inc. (NYSE: HPQ) is a global technology leader and creator of solutions that enable people to bring their ideas to life and connect to the things that matter most. Operating in more than 170 countries, HP delivers a wide range of innovative and sustainable devices, services and subscriptions for personal computing, printing, 3D printing, hybrid work, gaming, and more. For more information, please visit:


Globe and Mail
2 hours ago
- Globe and Mail
Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead?
Those who invest in shares of Tesla Inc. (NASDAQ: TSLA) know that they are signed up for one of the wildest roller coaster rides in the stock market today, not only because the stock has been historically volatile but also because the company's CEO, Elon Musk, is starting to get involved in other areas that could potentially turn his attention away from what needs to be done to secure Tesla's leadership and future. [content-module:CompanyOverview|NASDAQ:TSLA] As most are aware, Musk has resigned from his role in a special government agency called the Department of Government Efficiency (DOGE, for short). While the intentions were good regarding the type of work this agency was to accomplish, disagreements between Musk and President Trump have driven two opposing views to a volatile week in Tesla stock, leaving some shareholders to incur losses as collateral damage. Seasoned Wall Street participants would see the recent panic as an opportunity in the technology sector, especially for shareholders eyeing lower prices. For Tesla, however, this is where the charts become particularly useful. This is important, especially when viewed through an auction lens, because there is an obvious price that Tesla could reach before providing an optimal entry point. Gaming: The Future of Tesla Now that Musk can focus his energy on Tesla's development, one clear objective will be fulfilled in the coming months and quarters. The race to make the robotaxi dream a reality should return to the CEO's forefront, especially as new competition has entered the scene. Waymo, an autonomous driving platform owned by Alphabet Inc. (NASDAQ: GOOGL), has already made significant progress in this space, averaging up to 250,000 rides per week. Whether it is due to technological superiority, market share, or sheer adoption from end users, Tesla now has a lot of ground to make up in this regard. This is one positive catalyst investors can look forward to today, especially as Musk is set to come back to the ground floor at Tesla. With this in mind, investors should still command a price for the stock that prices out most (if not all) of the potential downside that could arise from this current political feud. With a robotaxi announcement expected in the coming weeks of June 2025, it is high time for investors to strategize their positioning in the stock before the information spreads out more quickly than they can react to it. For this reason, the following technical level should also be kept in mind. Where Tesla Can Be Bought Examining the one-year chart for Tesla, investors can identify a significant inefficiency. During late April 2025, the price jumped aggressively from $259 per share to $288 per share in a matter of hours, creating a pattern that some would call a buy-side imbalance, where the auction left little to no time for investors to enter and chase the upward momentum in price. On a psychological level, this means there are still bulls waiting on the sidelines for this price, making it a mental and emotional anchor for buy orders to be executed again. In fact, the $270 mark represented solid support due to this development, where impatient buyers couldn't wait to retest the lower end of the breakout and had to get in. After falling by roughly 15% in one week, the $270 area acted as a backstop for further selling, accurately fulfilling this technical and psychological setup. Therefore, those looking to buy have two choices from today's $295 per share price. One option is to make room for the price to move up toward the $310 mark again, where the opposite pattern formed. On the way down, numerous sell-side inefficiencies formed, as a fast auction didn't allow sellers to exit and cut their losses. Given the uncertainty, it wouldn't be too far from reality to expect these beaten-down bulls to revisit that price before letting go of their shares. [content-module:TradingView|NASDAQ:TSLA] So now investors can watch the reaction in Tesla's price in this range; if it continues to act as 'resistance,' then they can rest assured that the lower price area near $270 will be tested again. At this point, they will have another incentive to open new positions on the long side. Here's a good sign that supports this view: up to $20 billion of institutional buying took place over the recent quarter for Tesla stock, a period that overlaps with this inefficiency, with the stock reaching the $270 mark, indicating a footprint of institutional liquidity advantages being taken. The map is laid out, and at 60% of its 52-week high, Tesla stock offers new investors a great risk-to-reward ratio moving forward, especially with a new $500 per share price target set by Dan Ives, an analyst from Wedbush Securities as of early June 2025. In his view, Tesla promises a rally of up to 70% from its current level. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...